Literature DB >> 10651631

Disulfide bridge engineering in the tachykinin NK1 receptor.

C E Elling1, U Raffetseder, S M Nielsen, T W Schwartz.   

Abstract

As in most other seven-transmembrane receptors, the central disulfide bridge from the extracellular end of TM-III to the middle of the second extracellular loop was essential for ligand binding in the NK1 receptor. However, introduction of "extra", single Cys residues in the second extracellular loop, at positions where disease-associated Cys substitutions impair receptor function in the vasopressin V2 receptor and in rhodopsin, did not cause mispairing with the Cys residues involved in this central disulfide bridge. Cys residues were introduced in the N-terminal extension and in the third extracellular loop, respectively, in such a way that disulfide bridge formation could be monitored by loss of substance P binding and breakage of the bridge could be monitored by gain of ligand binding. This disulfide bridge formed spontaneously in the whole population of receptors and could be titrated with low concentrations of reducing agent, dithiothreitol. Another putative disulfide bridge "switch" was constructed at the extracellular ends of TM-V and -VI, i.e., at positions where a high-affinity zinc site previously had been constructed with His substitutions. Disulfide bridge formation at this position, monitored by loss of binding of the nonpeptide antagonist [3H]LY303.870, occurred spontaneously only in a small fraction of the receptors. It is concluded that disulfide bridges form readily between Cys residues introduced appropriately in the N-terminal extension and the third extracellular loop, whereas they form with more difficulty between Cys residues placed at the extracellular ends of the transmembrane segments even at positions where high-affinity metal ion sites can be constructed with His residues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651631     DOI: 10.1021/bi991777b

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras.

Authors:  S M Nielsen; L Z Nielsen; S A Hjorth; M H Perrin; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

2.  Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.

Authors:  M Germana Paterlini
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

Review 3.  Lifting the lid on GPCRs: the role of extracellular loops.

Authors:  M Wheatley; D Wootten; M T Conner; J Simms; R Kendrick; R T Logan; D R Poyner; J Barwell
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor.

Authors:  Sarah J Paulsen; Mette M Rosenkilde; Jesper Eugen-Olsen; Thomas N Kledal
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Modulation of constitutive activity and signaling bias of the ghrelin receptor by conformational constraint in the second extracellular loop.

Authors:  Jacek Mokrosiński; Thomas M Frimurer; Bjørn Sivertsen; Thue W Schwartz; Birgitte Holst
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

6.  Experimental determination of the vertical alignment between the second and third transmembrane segments of muscle nicotinic acetylcholine receptors.

Authors:  Nelli Mnatsakanyan; Michaela Jansen
Journal:  J Neurochem       Date:  2013-04-30       Impact factor: 5.372

7.  Mapping substance P binding sites on the neurokinin-1 receptor using genetic incorporation of a photoreactive amino acid.

Authors:  Louise Valentin-Hansen; Minyoung Park; Thomas Huber; Amy Grunbeck; Saranga Naganathan; Thue W Schwartz; Thomas P Sakmar
Journal:  J Biol Chem       Date:  2014-05-15       Impact factor: 5.157

8.  Crystal structure of the human NK1 tachykinin receptor.

Authors:  Jie Yin; Karen Chapman; Lindsay D Clark; Zhenhua Shao; Dominika Borek; Qingping Xu; Junmei Wang; Daniel M Rosenbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-11       Impact factor: 12.779

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.